405 total citations 31 papers, 308 citations indexed
About
M. Bayés is a scholar working on Genetics, Molecular Biology and Pharmacology.
According to data from OpenAlex, M. Bayés has authored 31 papers receiving a total of 308 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 4 papers in Molecular Biology and 4 papers in Pharmacology. Recurrent topics in M. Bayés's work include Chronic Lymphocytic Leukemia Research (3 papers), Eosinophilic Disorders and Syndromes (2 papers) and Urticaria and Related Conditions (2 papers). M. Bayés is often cited by papers focused on Chronic Lymphocytic Leukemia Research (3 papers), Eosinophilic Disorders and Syndromes (2 papers) and Urticaria and Related Conditions (2 papers). M. Bayés collaborates with scholars based in Italy, Spain and United States. M. Bayés's co-authors include X Rabasseda, J. Prous, J. Castañer, P.A. Leeson, J. Bolós, J. Silvestre, M. Barbanoj, Lee J. Martin, Ignasi Gich and David Mauleón and has published in prestigious journals such as Clinical Drug Investigation, Drugs of the Future and PubMed.
In The Last Decade
M. Bayés
30 papers
receiving
291 citations
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of M. Bayés's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Bayés with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Bayés more than expected).
This network shows the impact of papers produced by M. Bayés. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Bayés. The network helps show where M. Bayés may publish in the future.
Co-authorship network of co-authors of M. Bayés
This figure shows the co-authorship network connecting the top 25 collaborators of M. Bayés.
A scholar is included among the top collaborators of M. Bayés based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with M. Bayés. M. Bayés is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Bolós, J., et al.. (2007). Satavaptan. Drugs of the Future. 32(1). 26–26.4 indexed citations
2.
Bayés, M., et al.. (2007). Plerixafor Hydrochloride. Drugs of the Future. 32(2). 123–123.1 indexed citations
3.
Bolós, J., et al.. (2006). Terutroban sodium. Drugs of the Future. 31(10). 867–867.8 indexed citations
4.
Revill, Peter, et al.. (2006). Gabapentin Enacarbil. Drugs of the Future. 31(9). 771–771.5 indexed citations
5.
Castañer, J., et al.. (2006). Sarizotan Hydrochloride. Drugs of the Future. 31(4). 314–314.5 indexed citations
6.
Leeson, P.A., et al.. (2005). AERx-Insulin. Drugs of the Future. 30(7). 673–673.1 indexed citations
7.
Davies, Susan L., J. Castañer, Jean‐Sébastien Silvestre, & M. Bayés. (2005). Etravirine. Drugs of the Future. 30(5). 462–462.1 indexed citations
8.
Castañer, J., et al.. (2004). Exatecan Mesilate. Drugs of the Future. 29(1). 9–9.1 indexed citations
9.
Castañer, J., et al.. (2004). Deferasirox. Drugs of the Future. 29(4). 331–331.2 indexed citations
10.
Bayés, M., X Rabasseda, & J. Prous. (2004). Gateways to clinical trials.. PubMed. 26(1). 129–11.169 indexed citations
11.
Bayés, M., et al.. (2003). Agomelatine. Drugs of the Future. 28(1). 7–7.11 indexed citations
12.
Castañer, J., et al.. (2003). Eszopiclone. Drugs of the Future. 28(7). 640–640.2 indexed citations
13.
Castañer, J., et al.. (2003). CC-5013. Drugs of the Future. 28(5). 425–425.1 indexed citations
14.
Cullell-Young, Martín, M. Bayés, & P.A. Leeson. (2003). Lanthanum Carbonate. Drugs of the Future. 28(3). 224–224.2 indexed citations
15.
Leeson, P.A., et al.. (2002). Pegaptanib Sodium. Drugs of the Future. 27(9). 841–841.2 indexed citations
16.
Castañer, J., et al.. (2002). Tecadenoson. Drugs of the Future. 27(9). 846–846.9 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.